Vienna, Austria – Building work on Biomay’s new headquarters and biotech manufacturing facility in Aspern Seestadt, Vienna, is progressing on schedule. Seven months after the groundbreaking ceremony in September 2020, the constructing shell has now been accomplished. Ongoing actions are presently targeted on the inside works and the set up of the complicated warmth, air flow and air con (HVAC) and utility methods.
Building Undertaking of Biomay’s Manufacturing Facility Totally on Schedule
Dr. Hans Huber, Chief Govt Officer of Biomay mentioned: “We’re delighted and impressed to witness the fast and well timed progress of our constructing undertaking. Inner and exterior engineering groups and the development employees are doing a wonderful job. It’s a pleasure to see how all of the group members are working collectively successfully in a concerted effort to satisfy Biomay’s objectives when it comes to schedule, high quality and finances. Seeing the satisfying progress, we’re extremely assured that the remaining half of the undertaking will keep on observe as nicely.”
As for the months to come back, the constructing as such is deliberate to be accomplished in September 2021, adopted by the manufacturing gear and course of utilities to be put in by Q3/2021. Biomay and its workers will transfer to the brand new web site on the finish of this yr. After commissioning and qualification, the corporate will begin up manufacturing operations for its purchasers in Q1/2022.
Concerning the Facility
Various parallel GMP manufacturing traces will probably be erected on a complete flooring space of about 4000 sq. meters, rising Biomay’s capacities by an element of 10 with respect to batch measurement and quantity (gross bioreactor scales: 5L, 50L, 150L and 750L). Moreover, a devoted space of the constructing will enable the manufacturing of progressive, personalised (patient-specific) batches.
Biomay AG is a biopharmaceutical contract improvement and manufacturing group (CDMO) with worldwide attain. Specifically, Biomay is acknowledged as provider for plasmid DNA (pDNA), recombinant proteins and messenger RNA (mRNA). Biomay’s purchasers embrace start-ups, midsize biotech firms and multinational enterprises, predominantly from Europe and the US. Beside manufacturing of energetic elements and drug merchandise in keeping with GMP requirements, the corporate presents course of and assay improvement in addition to manufacturing of microbial cell banks.